Details of the Drug
General Information of Drug (ID: DM3URJG)
Drug Name |
2,3-Dihydro-1H-indol-5-ol
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Indolin-5-ol; 172078-33-0; 2,3-dihydro-1H-indol-5-ol; 2,3-Dihydroindol-5-ol; 1H-Indol-5-ol,2,3-dihydro-; CHEMBL19331; AK-60844; 5-Indolinol; 5-hydroxyindoline; SCHEMBL59263; 2,3-Dihydro-1H-indole-5-ol; 2,3-dihydro-1 H-indol-5-ol; CTK4D4118; DTXSID40434426; MolPort-000-003-182; MPCXQPXCYDDJSR-UHFFFAOYSA-N; 1H-Indol-5-ol, 2,3-dihydro-; 5-hydroxy-2,3-dihydro-1H-indole; KS-00000ML8; ZINC13462664; FCH845722; 8845AA; BDBM50291681; ANW-58857; AKOS006279674; CS-W007244; CHM0007709; AJ-63836; SC-26235; 1H-INDOL-5-OL,2,3-DIHYDRO-,; KB-12380
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 135.16 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||